These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

147 related items for PubMed ID: 18221059

  • 1. Integrin alpha v beta 3 antagonists for anti-angiogenic cancer treatment.
    Hsu AR, Veeravagu A, Cai W, Hou LC, Tse V, Chen X.
    Recent Pat Anticancer Drug Discov; 2007 Jun; 2(2):143-58. PubMed ID: 18221059
    [Abstract] [Full Text] [Related]

  • 2. Anti-angiogenic cancer therapy based on integrin alphavbeta3 antagonism.
    Cai W, Chen X.
    Anticancer Agents Med Chem; 2006 Sep; 6(5):407-28. PubMed ID: 17017851
    [Abstract] [Full Text] [Related]

  • 3. Suppression of tumor angiogenesis through the inhibition of integrin function and signaling in endothelial cells: which side to target?
    Rüegg C, Dormond O, Foletti A.
    Endothelium; 2002 Sep; 9(3):151-60. PubMed ID: 12380640
    [Abstract] [Full Text] [Related]

  • 4. Ligands for mapping alphavbeta3-integrin expression in vivo.
    Schottelius M, Laufer B, Kessler H, Wester HJ.
    Acc Chem Res; 2009 Jul 21; 42(7):969-80. PubMed ID: 19489579
    [Abstract] [Full Text] [Related]

  • 5. Integrin-Targeted Peptide- and Peptidomimetic-Drug Conjugates for the Treatment of Tumors.
    Arosio D, Manzoni L, Corno C, Perego P.
    Recent Pat Anticancer Drug Discov; 2017 Jul 21; 12(2):148-168. PubMed ID: 28164756
    [Abstract] [Full Text] [Related]

  • 6. Integrin alpha v beta 3 as a therapeutic target for blocking tumor-induced angiogenesis.
    Kumar CC.
    Curr Drug Targets; 2003 Feb 21; 4(2):123-31. PubMed ID: 12558065
    [Abstract] [Full Text] [Related]

  • 7. The alpha v integrin antagonists as novel anticancer agents: an update.
    Kerr JS, Slee AM, Mousa SA.
    Expert Opin Investig Drugs; 2002 Dec 21; 11(12):1765-74. PubMed ID: 12457436
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Integrin alpha(v)beta(3)-Targeted Cancer Therapy.
    Liu Z, Wang F, Chen X.
    Drug Dev Res; 2008 Dec 21; 69(6):329-339. PubMed ID: 20628538
    [Abstract] [Full Text] [Related]

  • 11. Endothelial cell integrins and COX-2: mediators and therapeutic targets of tumor angiogenesis.
    Rüegg C, Dormond O, Mariotti A.
    Biochim Biophys Acta; 2004 Mar 04; 1654(1):51-67. PubMed ID: 14984767
    [Abstract] [Full Text] [Related]

  • 12. Alphavbeta3 integrin blocking inhibits apoptosis and induces autophagy in murine breast tumor cells.
    Lino RLB, Dos Santos PK, Pisani GFD, Altei WF, Cominetti MR, Selistre-de-Araújo HS.
    Biochim Biophys Acta Mol Cell Res; 2019 Dec 04; 1866(12):118536. PubMed ID: 31465809
    [Abstract] [Full Text] [Related]

  • 13. Small molecule integrin antagonists in cancer therapy.
    Paolillo M, Russo MA, Serra M, Colombo L, Schinelli S.
    Mini Rev Med Chem; 2009 Oct 04; 9(12):1439-46. PubMed ID: 19929817
    [Abstract] [Full Text] [Related]

  • 14. Evaluation of the anti-angiogenic properties of the new selective αVβ3 integrin antagonist RGDechiHCit.
    Santulli G, Basilicata MF, De Simone M, Del Giudice C, Anastasio A, Sorriento D, Saviano M, Del Gatto A, Trimarco B, Pedone C, Zaccaro L, Iaccarino G.
    J Transl Med; 2011 Jan 13; 9():7. PubMed ID: 21232121
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Anti-angiogenesis therapy in the Vx2 rabbit cancer model with a lipase-cleavable Sn 2 taxane phospholipid prodrug using α(v)β₃-targeted theranostic nanoparticles.
    Pan D, Schmieder AH, Wang K, Yang X, Senpan A, Cui G, Killgore K, Kim B, Allen JS, Zhang H, Caruthers SD, Shen B, Wickline SA, Lanza GM.
    Theranostics; 2014 Jan 13; 4(6):565-78. PubMed ID: 24723979
    [Abstract] [Full Text] [Related]

  • 17. Small molecule alpha(v) integrin antagonists: novel anticancer agents.
    Kerr JS, Slee AM, Mousa SA.
    Expert Opin Investig Drugs; 2000 Jun 13; 9(6):1271-9. PubMed ID: 11060742
    [Abstract] [Full Text] [Related]

  • 18. Alphavbeta3 integrin antagonist S247 decreases colon cancer metastasis and angiogenesis and improves survival in mice.
    Reinmuth N, Liu W, Ahmad SA, Fan F, Stoeltzing O, Parikh AA, Bucana CD, Gallick GE, Nickols MA, Westlin WF, Ellis LM.
    Cancer Res; 2003 May 01; 63(9):2079-87. PubMed ID: 12727823
    [Abstract] [Full Text] [Related]

  • 19. (64)Cu-labeled tetrameric and octameric RGD peptides for small-animal PET of tumor alpha(v)beta(3) integrin expression.
    Li ZB, Cai W, Cao Q, Chen K, Wu Z, He L, Chen X.
    J Nucl Med; 2007 Jul 01; 48(7):1162-71. PubMed ID: 17574975
    [Abstract] [Full Text] [Related]

  • 20. Radiolabeled multimeric cyclic RGD peptides as integrin alphavbeta3 targeted radiotracers for tumor imaging.
    Liu S.
    Mol Pharm; 2006 Jul 01; 3(5):472-87. PubMed ID: 17009846
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.